Skip to main content
Clinical Trials/NCT05358912
NCT05358912
Completed
Phase 4

Does Targeted Abdominal Perfusion Pressure Reduce Renal Injury and Mortality in Septic Shock Patients? A Prospective Controlled Trial

Bozyaka Training and Research Hospital1 site in 1 country85 target enrollmentDecember 2, 2019

Overview

Phase
Phase 4
Intervention
Crystalloid Solutions
Conditions
Septic Shock
Sponsor
Bozyaka Training and Research Hospital
Enrollment
85
Locations
1
Primary Endpoint
Change of the Level of Acute Kidney Injury
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Septic shock is a clinical condition that is defined as a subset of sepsis that causes very high mortality and morbidity.

Surviving sepsis campaign guideline states that the target mean arterial pressure should be 65 mmHg and above in septic shock patients. It is known that abdominal pressure increases and perfusion of intra-abdominal organs decreases in septic shock patients.

With this study, we aim to investigate the effects of targeted abdominal perfusion pressure (60 mmHg and above) on renal injury, reversal of renal injury, liver functions and ultimately mortality in patients with septic shock.

Detailed Description

Patients diagnosed with septic shock according to "Surviving Sepsis Campaign Guidelines 2021" will be included in the study. Groups will be formed after the measurement of intra-abdominal pressure (IAP). Those with IAP of less than 8 mmHg will be assigned to the control group and treated according to mean arterial pressure. Those with IAP greater than 8 mmHg will be divided into two groups by computer-generated randomization (via randomizer.org). One group (Group MAP) will be treated according to mean arterial pressure and the other group (Group APP) will be treated according to abdominal perfusion pressure. In Group APP, maximum arterial pressure will be targeted as 130/85 mmHg. All patients will receive appropriate antibiotic therapy, fluid therapy and, vasopressor treatment as recommended in "Surviving Sepsis Campaign Guidelines 2021" and abdominal pressure measurement will be repeated every 12 hours. Age, sex, body mass index, cause of sepsis and comorbidities of all patients will be recorded. Patients will be followed for liver and kidney function tests, procalcitonin and lactate levels, daily SOFA (Sequential Organ Failure Assessment) calculations, length of stay (days), length of stay in mechanical ventilator (days), and 30 and 90 days mortality.

Registry
clinicaltrials.gov
Start Date
December 2, 2019
End Date
September 21, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Bozyaka Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Mehmet Uğur Bilgin

MD, Anesthesiology Specialist

Bozyaka Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of septicemia according to "Surviving Sepsis Campaign Guidelines 2021"
  • Age lower than 18

Exclusion Criteria

  • Reason of admission: Cardiac arrest
  • Pregnancy
  • Abdominal surgery in the past 90 days
  • Pre-diagnosis of end-stage renal disease
  • History of abdominal trauma
  • Body mass index of 30 and above
  • Trauma, bleeding or cerebrovascular event that causes increased intracranial pressure

Arms & Interventions

APP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target abdominal perfusion pressure is 65 mmHg and above.

Intervention: Crystalloid Solutions

Control

Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Vasopressor Agent

Control

Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Crystalloid Solutions

Control

Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Invasive Blood Pressure Monitoring

Control

Patients who are diagnosed with septic shock and who have intra-abdominal pressure of less than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Intra-Abdominal Pressure Monitoring

MAP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Vasopressor Agent

MAP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Crystalloid Solutions

MAP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Invasive Blood Pressure Monitoring

MAP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target mean arterial pressure is 65 mmHg and above.

Intervention: Intra-Abdominal Pressure Monitoring

APP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target abdominal perfusion pressure is 65 mmHg and above.

Intervention: Vasopressor Agent

APP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target abdominal perfusion pressure is 65 mmHg and above.

Intervention: Invasive Blood Pressure Monitoring

APP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target abdominal perfusion pressure is 65 mmHg and above.

Intervention: Intra-Abdominal Pressure Monitoring

APP Group

Patients who are diagnosed with septic shock and who have intra-abdominal pressure greater than 8 mmHg. Target abdominal perfusion pressure is 65 mmHg and above.

Intervention: Abdominal Perfusion Pressure

Outcomes

Primary Outcomes

Change of the Level of Acute Kidney Injury

Time Frame: up to 90 days

Kidney damage will be monitored according to the KDIGO (Kidney Disease Improving Global Outcomes) classification.

Mortality

Time Frame: at 90th day of admission

Mortality in first 90 days

Study Sites (1)

Loading locations...

Similar Trials